First report of IMI-1-producing colistin-resistant enterobacter clinical isolate in Ireland, March 2013

Eurosurveillance

Volumn 18, Issue 31, 2013, Pages

  Boo, T W ^a,b   O'Connell, N ^c   Power, L ^c   O'Connor, M ^c   King, J ^a   McGrath, E ^a   Hill, R ^d   Hopkins, K L ^d   Woodford, N ^d  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^d PHE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CARBAPENEM; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DISK DIFFUSION; ENTEROBACTER; ENTEROBACTERIACEAE; HUMAN; IMI 1 PRODUCING COLISTIN RESISTANT ENTEROBACTER ASBURIAE; IRELAND; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; URINARY TRACT INFECTION;

EID: 84881050917     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2013.18.31.20548     Document Type: Article

References (17)

1. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1 EUCAST; 2013.Available from: http://www.eucast.org/clinical-breakpoints
2. Rasmussen B.A, Bush K, Keeney D, Yang Y, Hare R, O'Gara C, et al. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother. 1996;40(9):2080-2086.PMid:8878585 PMCid:PMC163477
3. Aubron C, Poirel L, Ash R.H, Nordmann P. Carbapenemase-producing Enterobacteriaceae, U.S. rivers. Emerg Infect Dis. 2005; 11(2):260-264.http://dx.doi.org/10.3201/eid1102.030684PMid:15752444 PMCid:PMC3320444
4. Walther-Rasmussen J, Høiby N. Class A carbapenemases. J AntimicrobChemother. 2007;60(3):470-482.http://dx.doi.org/10.1093/jac/dkm226PMid:17595289
5. Yu Y.S, Du X.X, Zhou Z.H, Chen Y.G, Li L.J. First isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China. Antimicrob Agents Chemother. 2006;50(4):1610-1611.http://dx.doi.org/10.1128/AAC.50.4.1610-1611.2006PMid:16569898 PMCid:PMC1426974
6. Naas T, Cattoen C, Bernusset S, Cuzon G, Nordmann P. First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France. Antimicrob Agents Chemother. 2012;56(3):1664-1665.http://dx.doi.org/10.1128/AAC.06328-11PMid:22203599 PMCid:PMC3294893
7. Österblad M, Kirveskari J, Hakanen A.J, Tissari P, Vaara M, Jalava J. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008-11). J AntimicrobChemother. 2012;67(12):2860-2864.http://dx.doi.org/10.1093/jac/dks299PMid:22855858
8. Teo J.W, La M.V, Krishnan P, Ang B, Jureen R, Lin R.T. Enterobacter cloacae producing an uncommon class A carbapenemase, IMI-1, from Singapore. J Med Microbiol. 2013;62(Pt 7):1086-1088.http://dx.doi.org/10.1099/jmm.0.053363-0PMid:23558141
9. Bernusset S, Naas T, Tande D, Biessy H, Poirel L, Henry M, et al. Characterisation of carbapenemase IMI-2 in Enterobacter spp. clinical isolates from France. Abstr. P1238. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 31 Mar-3 Apr2012, London, United Kingdom.
10. Landman D, Georgescu C, Martin D.A, Quale J. Polymyxins revisited. ClinMicrobiol Rev. 2008;21(3):449-465.http://dx.doi.org/10.1128/CMR.00006-08PMid:18625681 PMCid:PMC2493081
11. Bogdanovich T, Adams-Haduch J.M, Tian G.B, Nguyen M.H, Kwak E.J, Muto C.A, et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniaebelonging to the international epidemic clone ST258. Clin Infect Dis. 2011;53(4):373-376.http://dx.doi.org/10.1093/cid/cir401PMid:21810751 PMCid:PMC3202324
12. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J Hosp Infect. 2010;76(1):70-73.http://dx.doi.org/10.1016/j.jhin.2010.03.021PMid:20705205
13. Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C, et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill. 2012;17(33):pii=20248. Available from: http://www.eurosurveillance.orgPMid:22913977
14. Reynolds R, Kidney A, Mushtaq S, and Bsac Extended Working Party on Resistance Surveillance. Surprisingly high prevalence of colistin resistance in Enterobacterspp. in the UK and Ireland.Abstr. 1311. 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27-30 Apr 2013, Berlin, Germany.
15. Falagas M.E, Kastoris A.C, Kapaskelis A.M, Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43-50.
16. Lu C.L, Liu C.Y, Huang Y.T, Liao C.H, Teng L.J, Turnidge J.D, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 2011;55(9):4295-4301.http://dx.doi.org/10.1128/AAC.00349-11PMid:21670185 PMCid:PMC3165352
17. Stock I, Gruger T, Wiedemann B. Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex. Int J Antimicrob Agents. 2001;18(6):537-545.http://dx.doi.org/10.1016/S0924-8579(01)00463-0